Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy

Abstract. Ingelman‐Sundberg M ( IMM, Karolinska Institutet, Stockholm, Sweden). Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J Intern Med 2001; 250: 186–200.

[1]  E. Pravatà,et al.  Reply , 2001, British Journal of Cancer.

[2]  M Heath-Chiozzi,et al.  Clinical application of pharmacogenetics. , 2001, Trends in molecular medicine.

[3]  Pui-Yan Kwok,et al.  Single-nucleotide polymorphisms in the public domain: how useful are they? , 2001, Nature Genetics.

[4]  N. Freimer,et al.  Screening a large reference sample to identify very low frequency sequence variants: comparisons between two genes , 2001, Nature Genetics.

[5]  Ann Daly,et al.  Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression , 2001, Nature Genetics.

[6]  R. Weinshilboum,et al.  Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[7]  C. Meisel,et al.  Frequency of single nucleotide polymorphisms in the P‐glycoprotein drug transporter MDR1 gene in white subjects , 2001, Clinical pharmacology and therapeutics.

[8]  D. Filliol,et al.  A Single Nucleotide Polymorphic Mutation in the Human μ-Opioid Receptor Severely Impairs Receptor Signaling* , 2001, The Journal of Biological Chemistry.

[9]  M. Oscarson.  Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: implications for interindividual differences in nicotine metabolism. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[10]  U. Meyer.  Pharmacogenetics and adverse drug reactions , 2000, The Lancet.

[11]  A. Kjellin,et al.  Omeprazole and CYP2C19 polymorphism: effects of long‐term treatment on gastrin, pepsinogen I, and chromogranin A in patients with acid related disorders , 2000, Alimentary pharmacology & therapeutics.

[12]  M. Pirmohamed,et al.  Adverse drug reactions as a cause of admission to an acute medical assessment unit: a pilot study , 2000, Journal of clinical pharmacy and therapeutics.

[13]  R. Tyndale,et al.  Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. , 2000, Molecular pharmacology.

[14]  D M Roden,et al.  A common polymorphism associated with antibiotic-induced cardiac arrhythmia. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[15]  R S Judson,et al.  Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[16]  W. Evans,et al.  Genetic Polymorphism of Thiopurine S-Methyltransferase: Molecular Mechanisms and Clinical Importance , 2000, Pharmacology.

[17]  Y. Wing,et al.  Occurrence of CYP2D6 gene duplication in Hong Kong Chinese. , 2000, Clinical chemistry.

[18]  S. Liggett.  Pharmacogenetics of Beta-1- and Beta-2-Adrenergic Receptors , 2000, Pharmacology.

[19]  T. Baglin,et al.  Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. , 2000, Blood.

[20]  M. Kool,et al.  A family of drug transporters: the multidrug resistance-associated proteins. , 2000, Journal of the National Cancer Institute.

[21]  S. Imaoka,et al.  The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6. , 2000, Archives of biochemistry and biophysics.

[22]  J. Azuma,et al.  CYP2D6 genotypes in a Japanese population: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10. , 2000, Pharmacogenetics.

[23]  R. Tyndale,et al.  Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking , 2000, Clinical pharmacology and therapeutics.

[24]  A. Roses.  Pharmacogenetics and the practice of medicine , 2000, Nature.

[25]  C. Heyser,et al.  mu-Opioid receptor knockout mice do not self-administer alcohol. , 2000, The Journal of pharmacology and experimental therapeutics.

[26]  I. Leclercq,et al.  CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. , 2000, The Journal of clinical investigation.

[27]  H. Sugimura,et al.  Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. , 2000, Clinical pharmacology and therapeutics.

[28]  U. Brinkmann,et al.  Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[29]  L. Bertilsson,et al.  Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes. , 2000, British journal of clinical pharmacology.

[30]  M. Ingelman-Sundberg,et al.  Duplication, multiduplication, and amplification of genes encoding drug-metabolizing enzymes: evolutionary, toxicological, and clinical pharmacological aspects. , 1999, Drug metabolism reviews.

[31]  L. Bertilsson,et al.  Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes. , 1999, Pharmacogenetics.

[32]  M. Relling,et al.  Pharmacogenomics: translating functional genomics into rational therapeutics. , 1999, Science.

[33]  M. Ingelman-Sundberg,et al.  Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine. , 1999, Pharmacogenetics.

[34]  M. Ingelman-Sundberg,et al.  Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. , 1999, Trends in pharmacological sciences.

[35]  Nicholas Schork,et al.  Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment , 1999, Nature Genetics.

[36]  M. Keating,et al.  MiRP1 Forms IKr Potassium Channels with HERG and Is Associated with Cardiac Arrhythmia , 1999, Cell.

[37]  G. Aithal,et al.  Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications , 1999, The Lancet.

[38]  R. Hauer,et al.  Genetic and Molecular Basis of Cardiac Arrhythmias: Impact on Clinical Management , 2022 .

[39]  P. Tu,et al.  No evidence for association of serotonin-2A receptor variant (102T/C) with schizophrenia or clozapine response in a Chinese population. , 1999, Neuroreport.

[40]  P. Padfield,et al.  Effect of the insertion/deletion polymorphism of the angiotensin-converting enzyme gene on response to angiotensin-converting enzyme inhibitors in patients with heart failure. , 1998, Journal of cardiovascular pharmacology.

[41]  M. Ratain,et al.  Pharmacogenetics and cancer chemotherapy. , 1998, European journal of cancer.

[42]  J. Miners,et al.  Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. , 1998, British journal of clinical pharmacology.

[43]  L. Bertilsson,et al.  10‐hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes , 1998, Clinical pharmacology and therapeutics.

[44]  J W Jukema,et al.  The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. , 1998, The New England journal of medicine.

[45]  M. Ingelman-Sundberg,et al.  Characterization of a human glutathione S-transferase mu cluster containing a duplicated GSTM1 gene that causes ultrarapid enzyme activity. , 1997, Molecular pharmacology.

[46]  M. Dahl,et al.  Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine. , 1997, Therapeutic drug monitoring.

[47]  M Ingelman-Sundberg,et al.  Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. , 1997, Pharmacogenetics.

[48]  D. Clapham,et al.  Ion channels--basic science and clinical disease. , 1997, The New England journal of medicine.

[49]  D. Classen,et al.  Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. , 1997, JAMA.

[50]  F. Cambien,et al.  Influence of the angiotensin II type 1 receptor gene polymorphism on the effects of perindopril and nitrendipine on arterial stiffness in hypertensive individuals. , 1996, Hypertension.

[51]  D. Collier,et al.  Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine , 1996, Neuroscience Letters.

[52]  M. Kreek.  Opiates, opioids and addiction. , 1996, Molecular psychiatry.

[53]  H. Scheffer,et al.  Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapy , 1996, The Lancet.

[54]  S. Gauthier,et al.  Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[55]  I. Ichikawa,et al.  Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. , 1995, The Journal of clinical investigation.

[56]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[57]  P Corvol,et al.  An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. , 1990, The Journal of clinical investigation.

[58]  C. Alm,et al.  Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in luman beings , 1989, Clinical pharmacology and therapeutics.

[59]  U. Meyer,et al.  MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylation. , 1987, Biochemical and biophysical research communications.

[60]  D. Collier,et al.  Pharmacogenetics for the Individualization of Psychiatric Treatment , 2001, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.

[61]  N. Malats,et al.  Why study metabolic susceptibility to cancer? , 1999, IARC scientific publications.

[62]  A. Marshall.  Getting the right drug into the right patient , 1998, Nature Biotechnology.

[63]  J Drews,et al.  The role of innovation in drug development. , 1997, Nature biotechnology.